Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioCision Announces Launch of HistoMailer™

Published: Monday, December 05, 2011
Last Updated: Monday, December 05, 2011
Bookmark and Share
The HistoMailer ensures simple, reliable transfer of tissue samples from the clinic to the laboratory.

BioCision, LLC has announced the launch of a new product - the HistoMailer - for safely sending tissue blocks for laboratory analysis.

The HistoMailer represents the first in a series of products designed to specifically address the need for safe, reliable transfer of samples between laboratories.

“We immediately recognized the need for a reliable tool to ship paraffin-embedded tissue blocks, which can melt during transport if not packaged correctly,” said Hugh Douglas, BioCision’s Chief Operating Officer.

Douglas continued, “The HistoMailer is a great fit with our expanding product portfolio of integrated solutions for biomedical sample handling from preparation to shipping. In the coming months, we will be introducing additional products to serve the specific tissue processing needs of clinical histology and pathology labs.”

The HistoMailer was originally developed by technicians at Mayo Medical Laboratories, which receives approximately 30,000 specimens per day from hospitals across the country.

According to Mayo Clinic Operations Coordinator Jeff Wills, “The HistoMailer provides end users with a value add when transporting lab specimens. The container is a full-circle tool, from start to finish and provides Mayo with the opportunity to become more green. Mayo’s Department of Laboratory Medicine and Pathology is currently using the technology, along with over one-thousand users across our client base.” Wills is also an inventor of the HistoMailer technology.

“Working with leading academic institutions to develop new tools and products is an important part of BioCision’s overall strategy to best serve biomedical researchers and clinicians,” said BioCision’s CEO Rolf Ehrhardt, MD, PhD.

BioCision specializes in benchtop products that ensure consistency, reproducibility and standardization of laboratory samples, with applications in drug discovery, and basic and clinical research.

Users benefit from high sample reproducibility and consistency - experiment to experiment, lab to lab and research/clinical site to site.

Mayo Clinic and Mr. J. Willis have a financial interest in the technology referenced in this news release.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CryoPod™ Takes Top Award at ESBB
Industry-first portable cryogenic biospecimen carrier with data logging capability receives second award for innovation.
Wednesday, October 21, 2015
BioCision Announces FDA Master File Acceptance for ThawSTAR
Submission to accelerate adoption of new point-of-care cell thawing technology.
Thursday, September 10, 2015
BioCision ThawSTAR Wins Top Honor for Innovation and Design
ThawSTAR wins gold from instrument business outlook (ibo) in the laboratory equipment industrial design category.
Thursday, August 27, 2015
BioCision to Develop Controlled-Rate Cell Freezing Systems for Cook Regentec Cell Therapy Vials
BioCision and Cook ink exclusive deal to combine technologies to standardize cell cryopreservation in closed-system vials.
Wednesday, July 29, 2015
BioCision to Collaborate with Celgene Cellular Therapeutics
Companies to collaborate on standardizing and de-risking cell thawing process for a Phase 2 cell therapy for the treatment of diabetic foot ulcers.
Wednesday, June 03, 2015
Brooks Automation, BioCision Announce Equity Investment and Strategic Collaboration
Brooks invests $4 million into BioCision to build strategic alignment in biobanking and sample handling.
Monday, March 24, 2014
BioCision Announces Two New U.S. Patents for Thermo-Conductive Products
New patents awarded for CoolSink® Plate Modules and ThermalTray™ Platforms.
Thursday, June 20, 2013
BioCision’s CoolProduct range now available from SANYO
BioCision, LLC have announced the signing of a product distribution agreement with SANYO E&E Europe BV, SANYO’s biomedical division in Europe. SANYO will be marketing the entire CoolProduct portfolio – a modular system of benchtop laboratory tools based on BioCision’s patented technology for temperature change and control of benchtop biomedical samples.
Wednesday, November 17, 2010
Scientific News
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Signals That Make Early Stem Cells Identified
Researchers at The Rockefeller University have identified a new mechanism by which cells are instructed during development to become stem cells
Healing Scarred Hearts
Findings suggest stem cells may one day be used to regenerate damaged tissue after heart attack.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!